SCHEMBL6167

SCHEMBL6167

CC(C)(C)OC(=O)NNCc1ccc(-c2nccs2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 3/20 0.53
GPR119 Q8TDV5 1/20 0.44
LOXL2 Q9Y4K0 1/20 0.43
GAA P10253 1/20 0.42
CYP17A1 P05093 1/20 0.42
LTA4H P09960 1/20 0.40
METAP1 P53582 1/20 0.40
ABL1 P00519 1/20 0.39
BCR P11274 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
FFAR1 O14842 1/20 0.39
SLC6A4 P31645 1/20 0.39
HDAC3 O15379 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC10 Q969S8 1/20 0.38
HDAC11 Q96DB2 1/20 0.38
HDAC8 Q9BY41 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8220821 0.88 ADRB2 (0.56) ADRB2GPR119LOXL2GAACYP17A1
SCHEMBL30807329 0.81 CA1 (0.51) ADRB2GPR119LTA4HL3MBTL1KDM4E
SCHEMBL8117503 0.80 CYP17A1 (0.57) ADRB2GPR119CYP17A1METAP1HDAC3
SCHEMBL8332495 0.79 METAP1 (0.42) GAAMETAP1L3MBTL1
SCHEMBL4749 0.79 HDAC1 (0.49) GPR119GAALTA4HHDAC3HDAC1
SCHEMBL6692 0.78 TRPV1 (0.44) GAACYP17A1ABL1BCRL3MBTL1
SCHEMBL6103 0.78 GPR119 (0.42) GPR119GAACYP17A1L3MBTL1HDAC1
SCHEMBL30637051 0.78 TRPV1 (0.44) GAACYP17A1ABL1BCRL3MBTL1
SCHEMBL6447258 0.78 HDAC1 (0.52) GAACYP17A1HDAC1
SCHEMBL17963188 0.77 CYP17A1 (0.53) GPR119GAACYP17A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1310905-C Antivirally active heterocyclic azahexane derivatives NOVARTIS AG (CH) 2007-04-18 CN disclosed
CN-1616453-A Antivirally active heterocyclic azahexane derivatives NOVARTIS AG (CH) 2005-05-18 CN disclosed
CN-1193010-C Heterocyclic azahexane derivatives with antiviral activity NOVARTIS AG (CH) 2005-03-16 CN disclosed
EP-0900210-B1 ANTIVIRALLY ACTIVE HETEROCYCLIC AZAHEXANE DERIVATIVES NOVARTIS AG (CH) 2005-02-09 EP disclosed
CN-1082508-C Heterocyclic azahexane derivatives with antiviral activity NOVARTIS AG (CH) 2002-04-10 CN disclosed
CN-1319587-A Heterocyclic azahexane derivatives with antiviral activity NOVARTIS AG (CH) 2001-10-31 CN disclosed
US-6300519-B1 REACTING HYDRAZINE DERIVATIVE WITH EPOXIDE COMPOUND NOVARTIS FINANCE CORPORATION 2001-10-09 US disclosed
US-6166004-A Combinations of HIV protease inhibitors with reverse transcriptase inhibitors NOVARTIS FINANCE CORPORATION (US) 2000-12-26 US disclosed
US-6110946-A AN ENZYME INHIBITORS OF RETROVIRAL ASPARTATE PROTEASE FOR THE TREATMENT OF AIDS NOVARTIS FINANCE CORPORATION (US) 2000-08-29 US disclosed
CN-1216539-A Heterocyclic azahexane derivatives with antiviral activity NOVARTIS AG (CH) 1999-05-12 CN disclosed
EP-0900210-A1 ANTIVIRALLY ACTIVE HETEROCYCLIC AZAHEXANE DERIVATIVES Novartis AG (CH) 1999-03-10 EP disclosed
US-5849911-A Antivirally active heterocyclic azahexane derivatives NOVARTIS FINANCE CORPORATION (US) 1998-12-15 US disclosed
WO-1997040029-A1 ANTIVIRALLY ACTIVE HETEROCYCLIC AZAHEXANE DERIVATIVES NOVARTIS AG (CH) 1997-10-30 WO disclosed